Danson, Sarah
Hook, Jane
Marshall, Helen
Smith, Alexandra
Bell, Sue
Rodwell, Simon
Corrie, Pippa
Funding for this research was provided by:
DH | NIHR | Health Technology Assessment Programme (15/57/66, 15/57/66, 15/57/66, 15/57/66, 15/57/66, 15/57/66, 15/57/66)
Article History
Received: 13 August 2019
Revised: 20 August 2019
Accepted: 23 August 2019
First Online: 17 September 2019
Competing interests
: The authors are co-applicants on the DANTE trial. S.D. has received conference and travel support from MSD, Pierre Fabre and BMS; and sat on advisory boards for MSD and BMS. P.C. has received speaker fees and sat on advisory boards for MSD, BMS, Novartis and Pierre Fabre. S.R. is CEO of the charity Melanoma Focus. The remaining authors declare no competing interests.
: Not applicable
: The DANTE study is funded by the National Institute for Health Research Health Technology Assessment (HTA) Programme (project number 15/57/66). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funder has not been involved in the writing of this article.
: Not applicable
: Not applicable